Charles River (CRL) reported Q4 FY2025 revenue of USD 994.2 million (-0.8%). GAAP operating margin was (28.5)% and net loss available to common shareholders was USD 276.6 million (loss per diluted share: USD 5.62), reflecting non-cash intangible asset impairments of USD 211.0 million and a non-cash goodwill impairment of USD 165.0 million. On a non-GAAP basis, operating margin was 18.1% and net income was USD 118.8 million (-13.0%), with diluted EPS of USD 2.39 (-10.2%). By segment in Q4, Research Models and Services revenue was USD 206.3 million (+1.0%), Discovery and Safety Assessment revenue was USD 591.6 million (-2.0%), and Manufacturing Solutions revenue was USD 196.4 million (+0.7%). Management highlighted “substantial improvement” in DSA net bookings in Q4, pointing to stabilization in biopharmaceutical demand, and said it is pursuing efficiency actions and selective acquisitions. For FY2025, revenue was USD 4.02 billion (-0.9%); GAAP net loss available to common shareholders was USD 144.3 million (loss per diluted share: USD 2.91), while non-GAAP net income was USD 512.3 million (-3.9%) with non-GAAP diluted EPS of USD 10.28 (-0.4%). CRL also issued FY2026 guidance, including reported revenue growth of at least flat to +1.5%, GAAP EPS of USD 6.30 to USD 6.80, and non-GAAP EPS of USD 10.70 to USD 11.20, excluding the impact of planned divestitures representing about 7% of FY2025 annual revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260218016453) on February 18, 2026, and is solely responsible for the information contained therein.